Infraredx said it inked a deal with HealthTrust Purchasing Group for its TVC imaging system, which uses both near-infrared spectroscopy and intravascular ultrasound to provide images of coronary blood vessels.

The deal calls for the TVC device to be made available to HealthTrust’s 1,400-member roster of acute care facilities, according to a press release.

"We are pleased to be selected by HealthTrust to provide our innovative TVC Imaging System now to more than 25 percent of the hospital healthcare facilities across the United States," president & CEO Don Southard said in prepared remarks. "Our contract will enable HealthTrust members access to our novel dual-modality intravascular imaging technology, which provides valuable information for physicians to make procedural and patient care decisions aimed at improving clinical outcomes and lowering healthcare costs."

The TVC system uses NIRS to detect lipid-core plaques and IVUS to visualize the vessel during percutaneous coronary interventions. It’s designed to reveal the structure of plaques and the degree of stenosis due to plaque build-up, according to the release.

Infraredx, which inked a resale deal for the TVC system with Philips Healthcare (NYSE:PHG) last year, said fatty lipid-core plaque is known to cause PCI complications; rupture of lipid-core plaque is associated with most heart attacks, the company said.

Japan’s Nipro Corp. (TYO:8086) put down a $25 million equity investment in the Burlington, Mass.-based medical device company in August 2013.